Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Multiple Sclerosis

  Free Subscription


16.09.2019

1 AJNR Am J Neuroradiol
3 Brain
1 Can J Neurol Sci
4 J Neuroimmunol
1 J Neurol
1 J Neurol Sci
4 Mult Scler
1 Nat Med
2 Neurology
1 PLoS One
1 Rev Neurol (Paris)


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJNR Am J Neuroradiol

  1. HAGIWARA A, Kamagata K, Shimoji K, Yokoyama K, et al
    White Matter Abnormalities in Multiple Sclerosis Evaluated by Quantitative Synthetic MRI, Diffusion Tensor Imaging, and Neurite Orientation Dispersion and Density Imaging.
    AJNR Am J Neuroradiol. 2019 Sep 12. pii: ajnr.A6209. doi: 10.3174/ajnr.A6209.
    PubMed     Text format     Abstract available


    Brain

  2. ROPELE S, Fazekas F
    Quantification of cortical damage in multiple sclerosis using DTI remains a challenge.
    Brain. 2019;142:1848-1850.
    PubMed     Text format    

  3. ELLIOTT C, Belachew S, Wolinsky JS, Hauser SL, et al
    Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Brain. 2019;142:2787-2799.
    PubMed     Text format     Abstract available

  4. PENNER IK, Hartung HP
    The dark side of the moon: looking beyond beneficial effects of cannabis use in multiple sclerosis.
    Brain. 2019;142:2552-2555.
    PubMed     Text format    


    Can J Neurol Sci

  5. BOSE G, Thebault SDX, Atkins HL, Freedman MS, et al
    Does resetting the immune system fix multiple sclerosis?
    Can J Neurol Sci. 2019 Sep 12:1-35. doi: 10.1017/cjn.2019.
    PubMed     Text format    


    J Neuroimmunol

  6. ZAROBKIEWICZ MK, Kowalska W, Halczuk P, Wos J, et al
    RORgammaT is overexpressed in iNKT and gammadelta T cells during relapse in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;337:577046.
    PubMed     Text format     Abstract available

  7. ABDEL-DAYEM MA, Shaker ME, Gameil NM
    Impact of interferon beta-1b, interferon beta-1a and fingolimod therapies on serum interleukins-22, 32alpha and 34 concentrations in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2019;337:577062.
    PubMed     Text format     Abstract available

  8. AFSHAR B, Khalifehzadeh-Esfahani Z, Seyfizadeh N, Rezaei Danbaran G, et al
    The role of immune regulatory molecules in multiple sclerosis.
    J Neuroimmunol. 2019;337:577061.
    PubMed     Text format     Abstract available

  9. LIANG H, Gao W, Liu X, Liu J, et al
    The GTF2I rs117026326 polymorphism is associated with neuromyelitis optica spectrum disorder but not with multiple sclerosis in a Northern Han Chinese population.
    J Neuroimmunol. 2019;337:577045.
    PubMed     Text format     Abstract available


    J Neurol

  10. GRANELLA F, Tsantes E, Graziuso S, Bazzurri V, et al
    Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey.
    J Neurol. 2019 Sep 7. pii: 10.1007/s00415-019-09526.
    PubMed     Text format     Abstract available


    J Neurol Sci

  11. VANOLI E, Montano N, De Angelis G, Badilini F, et al
    Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
    J Neurol Sci. 2019;405:116423.
    PubMed     Text format     Abstract available


    Mult Scler

  12. MARRIE RA, Tremlett H, Kingwell E, Schaffer SA, et al
    Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study.
    Mult Scler. 2019 Sep 13:1352458519876038. doi: 10.1177/1352458519876038.
    PubMed     Text format     Abstract available

  13. VAN GEEL F, Veldkamp R, Severijns D, Dalgas U, et al
    Day-to-day reliability, agreement and discriminative validity of measuring walking-related performance fatigability in persons with multiple sclerosis.
    Mult Scler. 2019 Sep 9:1352458519872465. doi: 10.1177/1352458519872465.
    PubMed     Text format     Abstract available

  14. LEURS CE, van Kempen ZL, Dekker I, Balk LJ, et al
    Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
    Mult Scler. 2017 Aug 1:1352458517726381. doi: 10.1177/1352458517726381.
    PubMed     Text format     Abstract available

  15. RODRIGUEZ-LEAL FA, Haase R, Thomas K, Eisele JC, et al
    Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Mult Scler. 2017 Jul 1:1352458517720043. doi: 10.1177/1352458517720043.
    PubMed     Text format     Abstract available


    Nat Med

  16. CASSOTTA A, Mikol V, Bertrand T, Pouzieux S, et al
    A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients.
    Nat Med. 2019;25:1402-1407.
    PubMed     Text format     Abstract available


    Neurology

  17. BATEMAN EM, Schleicher WE, Smith EJ, Sweet DR, et al
    Journal Club: MRI reveals acute inflammation in cortical lesions during early MS.
    Neurology. 2018;90:e724-e726.
    PubMed     Text format     Abstract available

  18. PFUHL C, Grittner U, Giess RM, Scheel M, et al
    Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis.
    Neurology. 2019 Sep 9. pii: WNL.0000000000008237.
    PubMed     Text format     Abstract available


    PLoS One

  19. SHI J, Wu X, Chen Y
    Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis.
    PLoS One. 2019;14:e0222288.
    PubMed     Text format     Abstract available


    Rev Neurol (Paris)

  20. SADOVNICK D
    The place of environmental factors in multiple sclerosis: Genes, environment and the interactions thereof in the etiology of multiple sclerosis.
    Rev Neurol (Paris). 2019 Sep 10. pii: S0035-3787(19)30807.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: